Novartis Feed

	Est. tid*
2026-04-24	07:00	Kvartalsrapport 2026-Q1
2026-01-29	N/A	Bokslutskommuniké 2025
2025-10-24	07:00	Kvartalsrapport 2025-Q3
2025-07-18	07:00	Kvartalsrapport 2025-Q2
2025-04-29	-	Kvartalsrapport 2025-Q1
2025-03-11	-	X-dag ordinarie utdelning NOVN 3.50 CHF
2025-03-07	-	Årsstämma
2025-01-31	-	Bokslutskommuniké 2024
2024-10-29	-	Kvartalsrapport 2024-Q3
2024-07-18	-	Kvartalsrapport 2024-Q2
2024-04-23	-	Kvartalsrapport 2024-Q1
2024-03-07	-	X-dag ordinarie utdelning NOVN 3.30 CHF
2024-03-05	-	Årsstämma
2024-01-31	-	Bokslutskommuniké 2023
2023-10-24	-	Kvartalsrapport 2023-Q3
2023-09-15	-	Extra Bolagsstämma
2023-07-18	-	Kvartalsrapport 2023-Q2
2023-05-07	-	Årsstämma
2023-04-25	-	Kvartalsrapport 2023-Q1
2023-03-09	-	X-dag ordinarie utdelning NOVN 3.20 CHF
2023-03-07	-	Årsstämma
2023-02-01	-	Bokslutskommuniké 2022
2022-10-25	-	Kvartalsrapport 2022-Q3
2022-07-19	-	Kvartalsrapport 2022-Q2
2022-04-26	-	Kvartalsrapport 2022-Q1
2022-03-08	-	X-dag ordinarie utdelning NOVN 3.10 CHF
2022-03-04	-	Årsstämma
2022-02-02	-	Bokslutskommuniké 2021
2021-10-26	-	Kvartalsrapport 2021-Q3
2021-07-21	-	Kvartalsrapport 2021-Q2
2021-04-27	-	Kvartalsrapport 2021-Q1
2021-03-04	-	X-dag ordinarie utdelning NOVN 3.00 CHF
2021-03-02	-	Årsstämma
2021-01-26	-	Bokslutskommuniké 2020
2020-10-27	-	Kvartalsrapport 2020-Q3
2020-07-21	-	Kvartalsrapport 2020-Q2
2020-04-28	-	Kvartalsrapport 2020-Q1
2020-03-03	-	X-dag ordinarie utdelning NOVN 2.95 CHF
2020-02-28	-	Årsstämma
2020-01-29	-	Bokslutskommuniké 2019
2019-10-22	-	Kvartalsrapport 2019-Q3
2019-07-18	-	Kvartalsrapport 2019-Q2
2019-04-24	-	Kvartalsrapport 2019-Q1

2025-05-27 13:56:11 Novartis announces commencement of tender offer to acquire Regulus Therapeutics 93,64 CHF | +1,69%

2025-05-15 15:00:00 New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline 89,36 CHF | -0,54%

2025-04-30 13:10:39 Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure 93,86 CHF | -0,41%

2025-04-03 02:13:15 Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) 98,23 CHF | +1,34%

2025-03-31 07:00:00 Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis 98,17 CHF | -0,34%

2025-03-28 17:52:27 FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer 98,50 CHF | +1,31%

2025-03-25 07:15:00 Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis 98,44 CHF | -0,53%

2025-03-21 00:11:47 Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) 99,58 CHF | +1,37%

2025-03-19 14:00:00 New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA 98,23 CHF | -0,45%

2025-03-07 15:11:56 Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut 100,51 CHF | +1,39%

2025-03-07 15:11:56 Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting 100,51 CHF | +1,39%

2025-02-28 15:00:00 Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) 97,50 CHF | -0,27%

2025-02-28 13:39:45 Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G) 97,50 CHF | -0,27%

2025-02-11 07:15:00 Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront 96,87 CHF | +0,14%

2025-01-31 07:00:00 Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen 95,95 CHF | +2,82%

2025-01-31 07:00:00 Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 95,95 CHF | +2,82%

2025-01-13 07:15:00 Novartis Entresto® US patent upheld by US Court of Appeals 90,75 CHF | -0,86%

2024-12-30 06:45:00 Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA 88,75 CHF | +0,40%

2024-12-10 15:00:00 Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer 89,55 CHF | -0,56%

2024-12-08 18:30:00 Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

2024-12-06 07:15:00 New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy 90,36 CHF | -0,36%

2024-11-27 07:15:00 Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence 92,01 CHF | +0,22%

2024-11-25 07:15:00 Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS 92,61 CHF | -0,94%

2024-11-21 07:00:00 Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth 91,48 CHF | +0,21%

2024-11-19 14:00:00 Novartis ranks first in 2024 Access to Medicine Index 91,37 CHF | +0,14%

2024-10-29 20:03:58 Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile 96,67 CHF | -2,16%

2024-10-29 07:00:00 Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben 96,67 CHF | -2,16%

2024-10-29 07:00:00 Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance 96,67 CHF | -2,16%

2024-10-27 01:50:00 Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial

2024-10-24 07:15:00 Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 99,11 CHF | -0,05%

2024-10-18 12:47:27 Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer 100,36 CHF | -0,67%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Novartis